sars cov 2 rna fragments  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    ATCC sars cov 2 rna fragments
    Flowchart of the magnetic-bead-based target extraction and preconcentration method. a, Magnetic carrier microbeads with 14 base pair long pulldown oligonucleotides. pd: pull-down sequence. b, <t>SARS-CoV-2</t> negative human nasopharyngeal swab (NPS) solution and synthetic SARS-CoV-2 RNA solution is mixed with the magnetic carrier beads and processed using heating, magnetic pulldown, and washing steps to extract targets onto beads (details see main text). c, Target-functionalized magnetic carrier beads for detection on optofluidic nanopore chip.
    Sars Cov 2 Rna Fragments, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 rna fragments/product/ATCC
    Average 94 stars, based on 4 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 rna fragments - by Bioz Stars, 2022-09
    94/100 stars

    Images

    1) Product Images from "Optical trapping assisted label-free and amplification-free detection of SARS-CoV-2 RNAs with an optofluidic nanopore sensor"

    Article Title: Optical trapping assisted label-free and amplification-free detection of SARS-CoV-2 RNAs with an optofluidic nanopore sensor

    Journal: Biosensors & Bioelectronics

    doi: 10.1016/j.bios.2021.113588

    Flowchart of the magnetic-bead-based target extraction and preconcentration method. a, Magnetic carrier microbeads with 14 base pair long pulldown oligonucleotides. pd: pull-down sequence. b, SARS-CoV-2 negative human nasopharyngeal swab (NPS) solution and synthetic SARS-CoV-2 RNA solution is mixed with the magnetic carrier beads and processed using heating, magnetic pulldown, and washing steps to extract targets onto beads (details see main text). c, Target-functionalized magnetic carrier beads for detection on optofluidic nanopore chip.
    Figure Legend Snippet: Flowchart of the magnetic-bead-based target extraction and preconcentration method. a, Magnetic carrier microbeads with 14 base pair long pulldown oligonucleotides. pd: pull-down sequence. b, SARS-CoV-2 negative human nasopharyngeal swab (NPS) solution and synthetic SARS-CoV-2 RNA solution is mixed with the magnetic carrier beads and processed using heating, magnetic pulldown, and washing steps to extract targets onto beads (details see main text). c, Target-functionalized magnetic carrier beads for detection on optofluidic nanopore chip.

    Techniques Used: Sequencing, Chromatin Immunoprecipitation

    SARS-CoV-2 nanopore TACRE assay. a, Real-time translocations of SARS-CoV-2 RNAs from TACRE method and control experiment. The gray region in the TACRE trace represents the 150s heating period for target release. b, Number of translocations from SARS-CoV-2 RNAs in bulk solution at different concentrations within 360s detection time window. c, Detection of SARS-CoV-2 RNAs at different initial concentrations with TACRE method. (Circles: data; crosses: predicted number of events). d, Number of translocations (red solid circles) vs initial target concentration normalized to the case of 10 trapped beads and 20 RNAs/bead. Purple solid line: expected number of translocations in ( c ) after normalization, which is 200 for all the concentrations. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Figure Legend Snippet: SARS-CoV-2 nanopore TACRE assay. a, Real-time translocations of SARS-CoV-2 RNAs from TACRE method and control experiment. The gray region in the TACRE trace represents the 150s heating period for target release. b, Number of translocations from SARS-CoV-2 RNAs in bulk solution at different concentrations within 360s detection time window. c, Detection of SARS-CoV-2 RNAs at different initial concentrations with TACRE method. (Circles: data; crosses: predicted number of events). d, Number of translocations (red solid circles) vs initial target concentration normalized to the case of 10 trapped beads and 20 RNAs/bead. Purple solid line: expected number of translocations in ( c ) after normalization, which is 200 for all the concentrations. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Techniques Used: Concentration Assay

    Optical trapping assisted nanopore capture rate enhancement (TACRE) platform. a, Optofluidic chip with connected solid-core (SC, gray) and liquid-core (LC, blue) waveguides. Reservoirs are attached over channel outlets and nanopore (NP) location. Voltages V EK and V NP are applied for electrokinetic delivery of bead-bound targets to the nanopore and translocation of released targets through nanopore, respectively. A light beam guided through the LC waveguide traps and collects carrier microbeads at the nanopore location. b, Closeup of TACRE process at NP location: targets are released from the beads while beads are trapped by the optical beam in the fluidic channel. Region (I): targets inside this region at the beginning of the experiment can diffuse to the nanopore capture volume within the duration of the experiment. Region (II): nanopore capture volume for particle translocations. c, SEM image of a terraced micro-well to create thin membrane for ion milling of 20 nm nanopore (inset). d, Baseline-corrected nanopore current for SARS-CoV-2 RNA segments translocating through the pore. Red dots mark individual RNA molecules identified by custom peak-finding algorithm. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Figure Legend Snippet: Optical trapping assisted nanopore capture rate enhancement (TACRE) platform. a, Optofluidic chip with connected solid-core (SC, gray) and liquid-core (LC, blue) waveguides. Reservoirs are attached over channel outlets and nanopore (NP) location. Voltages V EK and V NP are applied for electrokinetic delivery of bead-bound targets to the nanopore and translocation of released targets through nanopore, respectively. A light beam guided through the LC waveguide traps and collects carrier microbeads at the nanopore location. b, Closeup of TACRE process at NP location: targets are released from the beads while beads are trapped by the optical beam in the fluidic channel. Region (I): targets inside this region at the beginning of the experiment can diffuse to the nanopore capture volume within the duration of the experiment. Region (II): nanopore capture volume for particle translocations. c, SEM image of a terraced micro-well to create thin membrane for ion milling of 20 nm nanopore (inset). d, Baseline-corrected nanopore current for SARS-CoV-2 RNA segments translocating through the pore. Red dots mark individual RNA molecules identified by custom peak-finding algorithm. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Techniques Used: Chromatin Immunoprecipitation, Translocation Assay

    2) Product Images from "Mitoxantrone modulates a heparan sulfate-spike complex to inhibit SARS-CoV-2 infection"

    Article Title: Mitoxantrone modulates a heparan sulfate-spike complex to inhibit SARS-CoV-2 infection

    Journal: Scientific Reports

    doi: 10.1038/s41598-022-10293-x

    Mitoxantrone inhibits the entry of SARS-CoV-2 into a lung epithelial cell line. (A) Cells grown in monolayer were treated with Mitoxantrone (200 nM) and then infected with SARS-CoV-2 (USA-WA1/2020) at an MOI of 0.1. Five hours later, cells were fixed and stained with rabbit anti-spike antibodies in combination with goat anti-rabbit IgG conjugated with Alexa Fluor 488 (left panels). (B) Quantification of spike fluorescence intensity in (A) . ****, p
    Figure Legend Snippet: Mitoxantrone inhibits the entry of SARS-CoV-2 into a lung epithelial cell line. (A) Cells grown in monolayer were treated with Mitoxantrone (200 nM) and then infected with SARS-CoV-2 (USA-WA1/2020) at an MOI of 0.1. Five hours later, cells were fixed and stained with rabbit anti-spike antibodies in combination with goat anti-rabbit IgG conjugated with Alexa Fluor 488 (left panels). (B) Quantification of spike fluorescence intensity in (A) . ****, p

    Techniques Used: Infection, Staining, Fluorescence

    Mitoxantrone inhibits SARS-CoV-2 infection in an EpiAirway 3D tissue model. (A) A schematic diagram of the experimental design. (B) Remdesivir (2 μM) but not Bleomycin (100 μM) inhibits SARS-CoV-2 infection. 24 or 96 h after drug treatment and viral infection (MOI 0.1), the cell surface was washed. The viral titer (TCID50) in the wash was determined. (C,D) Mitoxantrone inhibits SARS-CoV-2 infection in the EpiAirway 3D model. TCID50 was determined either 24 h (C) or 96 h (D) after the organoids were treated with the drug at the indicated concentrations and then air-infected with SARS-CoV-2 at MOI 0.1 for 1 h. The cells were washed from the apical side to remove the virus in the cell exterior and then incubated for 24 (C) or 96 h (D) . Cells were rinsed from the apical side again and viral titers in the wash were determined. The dashed lines indicate the viral titer from cells infected without Mitoxantrone or in the presence of 2 mM Remdesivir (Rem.), as indicated. (E) Bleomycin (100 μM) but not Remdesivir (2 μM) induces cell death, releasing LDH as determined by a luciferase assay. *, p
    Figure Legend Snippet: Mitoxantrone inhibits SARS-CoV-2 infection in an EpiAirway 3D tissue model. (A) A schematic diagram of the experimental design. (B) Remdesivir (2 μM) but not Bleomycin (100 μM) inhibits SARS-CoV-2 infection. 24 or 96 h after drug treatment and viral infection (MOI 0.1), the cell surface was washed. The viral titer (TCID50) in the wash was determined. (C,D) Mitoxantrone inhibits SARS-CoV-2 infection in the EpiAirway 3D model. TCID50 was determined either 24 h (C) or 96 h (D) after the organoids were treated with the drug at the indicated concentrations and then air-infected with SARS-CoV-2 at MOI 0.1 for 1 h. The cells were washed from the apical side to remove the virus in the cell exterior and then incubated for 24 (C) or 96 h (D) . Cells were rinsed from the apical side again and viral titers in the wash were determined. The dashed lines indicate the viral titer from cells infected without Mitoxantrone or in the presence of 2 mM Remdesivir (Rem.), as indicated. (E) Bleomycin (100 μM) but not Remdesivir (2 μM) induces cell death, releasing LDH as determined by a luciferase assay. *, p

    Techniques Used: Infection, Incubation, Luciferase

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    ATCC sars cov 2 rna fragments
    Flowchart of the magnetic-bead-based target extraction and preconcentration method. a, Magnetic carrier microbeads with 14 base pair long pulldown oligonucleotides. pd: pull-down sequence. b, <t>SARS-CoV-2</t> negative human nasopharyngeal swab (NPS) solution and synthetic SARS-CoV-2 RNA solution is mixed with the magnetic carrier beads and processed using heating, magnetic pulldown, and washing steps to extract targets onto beads (details see main text). c, Target-functionalized magnetic carrier beads for detection on optofluidic nanopore chip.
    Sars Cov 2 Rna Fragments, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 rna fragments/product/ATCC
    Average 94 stars, based on 4 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 rna fragments - by Bioz Stars, 2022-09
    94/100 stars
      Buy from Supplier

    Image Search Results


    Flowchart of the magnetic-bead-based target extraction and preconcentration method. a, Magnetic carrier microbeads with 14 base pair long pulldown oligonucleotides. pd: pull-down sequence. b, SARS-CoV-2 negative human nasopharyngeal swab (NPS) solution and synthetic SARS-CoV-2 RNA solution is mixed with the magnetic carrier beads and processed using heating, magnetic pulldown, and washing steps to extract targets onto beads (details see main text). c, Target-functionalized magnetic carrier beads for detection on optofluidic nanopore chip.

    Journal: Biosensors & Bioelectronics

    Article Title: Optical trapping assisted label-free and amplification-free detection of SARS-CoV-2 RNAs with an optofluidic nanopore sensor

    doi: 10.1016/j.bios.2021.113588

    Figure Lengend Snippet: Flowchart of the magnetic-bead-based target extraction and preconcentration method. a, Magnetic carrier microbeads with 14 base pair long pulldown oligonucleotides. pd: pull-down sequence. b, SARS-CoV-2 negative human nasopharyngeal swab (NPS) solution and synthetic SARS-CoV-2 RNA solution is mixed with the magnetic carrier beads and processed using heating, magnetic pulldown, and washing steps to extract targets onto beads (details see main text). c, Target-functionalized magnetic carrier beads for detection on optofluidic nanopore chip.

    Article Snippet: A 10 μL aliquot of each sample was spiked with 10 μL of 1 × 109 copies/mL synthesized SARS-CoV-2 RNA fragments (ATCC) for a target concentration of 5 × 108 copies/mL ( b).

    Techniques: Sequencing, Chromatin Immunoprecipitation

    SARS-CoV-2 nanopore TACRE assay. a, Real-time translocations of SARS-CoV-2 RNAs from TACRE method and control experiment. The gray region in the TACRE trace represents the 150s heating period for target release. b, Number of translocations from SARS-CoV-2 RNAs in bulk solution at different concentrations within 360s detection time window. c, Detection of SARS-CoV-2 RNAs at different initial concentrations with TACRE method. (Circles: data; crosses: predicted number of events). d, Number of translocations (red solid circles) vs initial target concentration normalized to the case of 10 trapped beads and 20 RNAs/bead. Purple solid line: expected number of translocations in ( c ) after normalization, which is 200 for all the concentrations. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Journal: Biosensors & Bioelectronics

    Article Title: Optical trapping assisted label-free and amplification-free detection of SARS-CoV-2 RNAs with an optofluidic nanopore sensor

    doi: 10.1016/j.bios.2021.113588

    Figure Lengend Snippet: SARS-CoV-2 nanopore TACRE assay. a, Real-time translocations of SARS-CoV-2 RNAs from TACRE method and control experiment. The gray region in the TACRE trace represents the 150s heating period for target release. b, Number of translocations from SARS-CoV-2 RNAs in bulk solution at different concentrations within 360s detection time window. c, Detection of SARS-CoV-2 RNAs at different initial concentrations with TACRE method. (Circles: data; crosses: predicted number of events). d, Number of translocations (red solid circles) vs initial target concentration normalized to the case of 10 trapped beads and 20 RNAs/bead. Purple solid line: expected number of translocations in ( c ) after normalization, which is 200 for all the concentrations. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Article Snippet: A 10 μL aliquot of each sample was spiked with 10 μL of 1 × 109 copies/mL synthesized SARS-CoV-2 RNA fragments (ATCC) for a target concentration of 5 × 108 copies/mL ( b).

    Techniques: Concentration Assay

    Optical trapping assisted nanopore capture rate enhancement (TACRE) platform. a, Optofluidic chip with connected solid-core (SC, gray) and liquid-core (LC, blue) waveguides. Reservoirs are attached over channel outlets and nanopore (NP) location. Voltages V EK and V NP are applied for electrokinetic delivery of bead-bound targets to the nanopore and translocation of released targets through nanopore, respectively. A light beam guided through the LC waveguide traps and collects carrier microbeads at the nanopore location. b, Closeup of TACRE process at NP location: targets are released from the beads while beads are trapped by the optical beam in the fluidic channel. Region (I): targets inside this region at the beginning of the experiment can diffuse to the nanopore capture volume within the duration of the experiment. Region (II): nanopore capture volume for particle translocations. c, SEM image of a terraced micro-well to create thin membrane for ion milling of 20 nm nanopore (inset). d, Baseline-corrected nanopore current for SARS-CoV-2 RNA segments translocating through the pore. Red dots mark individual RNA molecules identified by custom peak-finding algorithm. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Journal: Biosensors & Bioelectronics

    Article Title: Optical trapping assisted label-free and amplification-free detection of SARS-CoV-2 RNAs with an optofluidic nanopore sensor

    doi: 10.1016/j.bios.2021.113588

    Figure Lengend Snippet: Optical trapping assisted nanopore capture rate enhancement (TACRE) platform. a, Optofluidic chip with connected solid-core (SC, gray) and liquid-core (LC, blue) waveguides. Reservoirs are attached over channel outlets and nanopore (NP) location. Voltages V EK and V NP are applied for electrokinetic delivery of bead-bound targets to the nanopore and translocation of released targets through nanopore, respectively. A light beam guided through the LC waveguide traps and collects carrier microbeads at the nanopore location. b, Closeup of TACRE process at NP location: targets are released from the beads while beads are trapped by the optical beam in the fluidic channel. Region (I): targets inside this region at the beginning of the experiment can diffuse to the nanopore capture volume within the duration of the experiment. Region (II): nanopore capture volume for particle translocations. c, SEM image of a terraced micro-well to create thin membrane for ion milling of 20 nm nanopore (inset). d, Baseline-corrected nanopore current for SARS-CoV-2 RNA segments translocating through the pore. Red dots mark individual RNA molecules identified by custom peak-finding algorithm. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Article Snippet: A 10 μL aliquot of each sample was spiked with 10 μL of 1 × 109 copies/mL synthesized SARS-CoV-2 RNA fragments (ATCC) for a target concentration of 5 × 108 copies/mL ( b).

    Techniques: Chromatin Immunoprecipitation, Translocation Assay

    Mitoxantrone inhibits the entry of SARS-CoV-2 into a lung epithelial cell line. (A) Cells grown in monolayer were treated with Mitoxantrone (200 nM) and then infected with SARS-CoV-2 (USA-WA1/2020) at an MOI of 0.1. Five hours later, cells were fixed and stained with rabbit anti-spike antibodies in combination with goat anti-rabbit IgG conjugated with Alexa Fluor 488 (left panels). (B) Quantification of spike fluorescence intensity in (A) . ****, p

    Journal: Scientific Reports

    Article Title: Mitoxantrone modulates a heparan sulfate-spike complex to inhibit SARS-CoV-2 infection

    doi: 10.1038/s41598-022-10293-x

    Figure Lengend Snippet: Mitoxantrone inhibits the entry of SARS-CoV-2 into a lung epithelial cell line. (A) Cells grown in monolayer were treated with Mitoxantrone (200 nM) and then infected with SARS-CoV-2 (USA-WA1/2020) at an MOI of 0.1. Five hours later, cells were fixed and stained with rabbit anti-spike antibodies in combination with goat anti-rabbit IgG conjugated with Alexa Fluor 488 (left panels). (B) Quantification of spike fluorescence intensity in (A) . ****, p

    Article Snippet: On the day of infection, cells were pre-treated with 200 nM mitoxantrone or as a control with DMSO for 30 min. After 30 min treatment, Vero E6 cells were infected with live SARS-Cov-2 (USA-WA1/2020) (ATCC #NR-52281) at an MOI of 0.1 for 5 h at 37 °C, 5% CO2.

    Techniques: Infection, Staining, Fluorescence

    Mitoxantrone inhibits SARS-CoV-2 infection in an EpiAirway 3D tissue model. (A) A schematic diagram of the experimental design. (B) Remdesivir (2 μM) but not Bleomycin (100 μM) inhibits SARS-CoV-2 infection. 24 or 96 h after drug treatment and viral infection (MOI 0.1), the cell surface was washed. The viral titer (TCID50) in the wash was determined. (C,D) Mitoxantrone inhibits SARS-CoV-2 infection in the EpiAirway 3D model. TCID50 was determined either 24 h (C) or 96 h (D) after the organoids were treated with the drug at the indicated concentrations and then air-infected with SARS-CoV-2 at MOI 0.1 for 1 h. The cells were washed from the apical side to remove the virus in the cell exterior and then incubated for 24 (C) or 96 h (D) . Cells were rinsed from the apical side again and viral titers in the wash were determined. The dashed lines indicate the viral titer from cells infected without Mitoxantrone or in the presence of 2 mM Remdesivir (Rem.), as indicated. (E) Bleomycin (100 μM) but not Remdesivir (2 μM) induces cell death, releasing LDH as determined by a luciferase assay. *, p

    Journal: Scientific Reports

    Article Title: Mitoxantrone modulates a heparan sulfate-spike complex to inhibit SARS-CoV-2 infection

    doi: 10.1038/s41598-022-10293-x

    Figure Lengend Snippet: Mitoxantrone inhibits SARS-CoV-2 infection in an EpiAirway 3D tissue model. (A) A schematic diagram of the experimental design. (B) Remdesivir (2 μM) but not Bleomycin (100 μM) inhibits SARS-CoV-2 infection. 24 or 96 h after drug treatment and viral infection (MOI 0.1), the cell surface was washed. The viral titer (TCID50) in the wash was determined. (C,D) Mitoxantrone inhibits SARS-CoV-2 infection in the EpiAirway 3D model. TCID50 was determined either 24 h (C) or 96 h (D) after the organoids were treated with the drug at the indicated concentrations and then air-infected with SARS-CoV-2 at MOI 0.1 for 1 h. The cells were washed from the apical side to remove the virus in the cell exterior and then incubated for 24 (C) or 96 h (D) . Cells were rinsed from the apical side again and viral titers in the wash were determined. The dashed lines indicate the viral titer from cells infected without Mitoxantrone or in the presence of 2 mM Remdesivir (Rem.), as indicated. (E) Bleomycin (100 μM) but not Remdesivir (2 μM) induces cell death, releasing LDH as determined by a luciferase assay. *, p

    Article Snippet: On the day of infection, cells were pre-treated with 200 nM mitoxantrone or as a control with DMSO for 30 min. After 30 min treatment, Vero E6 cells were infected with live SARS-Cov-2 (USA-WA1/2020) (ATCC #NR-52281) at an MOI of 0.1 for 5 h at 37 °C, 5% CO2.

    Techniques: Infection, Incubation, Luciferase